New hope for advanced breast cancer patients out of options
NCT ID NCT07117630
Summary
This study is testing whether adding a liver-supporting drug (L-Ornithine L-Aspartate) to two standard breast cancer medications can help control advanced breast cancer that has continued to grow despite previous treatment. It will involve 20 women whose cancer is hormone-sensitive and HER2-negative, and who have already tried and progressed on standard therapies. Researchers will measure if tumors shrink, how long the cancer stays controlled, and monitor side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.